EuropaBio, the European Association for Bioindustries, is proud to continue our platform for engaging patient and industry alike on pertinent healthcare debates: the Patient Bio-Forum. In this edition the focus will be on the impact of European Reference Networks (ERNs).
With an aim to facilitate discussion between patients and medical professionals across the EU, ERNs tackle rare disease head on. Creating a pooled, virtually accessible network of experts, ERNs demonstrate the power of collaboration in diagnosis complex and rare diseases. With the first ERNs having started in 2017, we anticipate a periodic evaluation during 2022/23. Similarly, this year the Commission have undertaken an evaluation of the Cross-border Healthcare Directive which establishes the legal basis of ERNs.
Against a backdrop of societal change, the EuropaBio Patient Bio-Forum convenes this October with a panel of experts representing patient, industry, EU and Member State perspectives on the challenges, achievements and opportunities the ERNs present.
AGENDA
Welcome and introduction (5 mins)
Panel Discussion (45 mins)
Biobreak/Slido Poll (5 mins)
Moderated Q&A (35 mins)
Closing remarks